Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
I have shared my views before on the ‘development and marketing of veterinary products’ company Dechra Pharmaceuticals (DPH), including noting in early September that ‘maybe it is just me finding it easier to appraise future human (than animal) demand scope, but I am going to keep on avoiding this one despite the recent share price falls’. And whilst the shares have romped hugely since their IPO early this century, the stock is down almost 30% during the last six months. So is today’s c. 38 quid share price – after the publication of first half numbers – now cheap or still expensive?
Already a member? Sign in
• All premium articles
• Tom Winnifrith’s Bearcast
• Access to all the entire nearly 13 year archive
• ShareProphets Daily Newsletter
Cancel any time
This area of the ShareProphets.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ShareProphets.com. ShareProphets.com does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ShareProphets.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ShareProphets.com and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.